Sermorelin Label Updates 2020 to 2026: FDA Status, Compounding Rules, and Safety Data

How Sermorelin Reached the Market and Lost Its NDA

Sermorelin acetate arrived on the U.S. Market through two distinct FDA approvals spanning the 1990s. The drug's departure from branded pharmaceutical channels set the stage for every regulatory question patients and prescribers face today.

The Two Original Approvals

The FDA first approved sermorelin acetate in 1997 under the brand name Geref Diagnostic (NDA 020-604) for the diagnostic assessment of growth hormone (GH) secretory capacity in patients with suspected GH deficiency [1]. An earlier formulation, Geref (sermorelin acetate for subcutaneous injection), had received approval for the treatment of idiopathic growth hormone deficiency in children with growth failure. The therapeutic version carried a labeled dose of 30 mcg/kg administered subcutaneously at bedtime. Walker et al. Published results from a multicenter pediatric trial in 1990 showing that sermorelin therapy produced clinically meaningful increases in growth velocity: 76% of GH-deficient children treated with sermorelin 30 mcg/kg/day reached a height velocity gain exceeding 2 cm/year above baseline over 12 months of treatment 1.

The 2008 Voluntary Withdrawal

EMD Serono, the manufacturer, voluntarily withdrew Geref from the U.S. Market in 2008. The FDA confirmed the withdrawal was for commercial reasons and not related to safety or efficacy concerns 2. That distinction matters. A safety-driven withdrawal triggers different regulatory consequences than a commercial one.

Because no NDA holder has marketed sermorelin since 2008, the FDA has had no occasion to issue label updates, safety communications, or Risk Evaluation and Mitigation Strategies (REMS) for the drug between 2020 and 2026. The "label" in the traditional sense is frozen at its last approved iteration.

Why No Label Updates Have Been Issued Since 2020

A drug without an active NDA sponsor does not receive FDA label revisions. This is not a gap in oversight. It is a structural feature of how U.S. Drug regulation works. The absence of updates between 2020 and 2026 reflects the fact that no pharmaceutical company holds the marketing rights.

The NDA Holder Gap

When EMD Serono relinquished the NDA, responsibility for pharmacovigilance reporting, adverse-event tracking, and label maintenance ceased at the sponsor level. The FDA Adverse Event Reporting System (FAERS) still collects voluntary reports on sermorelin from prescribers, compounding pharmacies, and patients. But without an NDA holder obligated to file periodic safety update reports, no formal mechanism exists to trigger a label change 3.

What the Original Label Contained

The last approved Geref Diagnostic label specified: sermorelin acetate for injection, 50 mcg per vial, reconstituted with sodium chloride diluent, administered as a single intravenous bolus for diagnostic purposes. Contraindications included hypersensitivity to sermorelin or any component. The label listed adverse reactions observed in clinical trials including facial flushing (in up to 1% of adult subjects), injection-site pain, and transient warmth at the injection site. The therapeutic Geref label for pediatric use documented injection-site reactions in approximately 16.5% of treated children, with pain, swelling, and redness as the most common complaints [1].

The Compounding Pharmacy Pathway: 503A and 503B Rules

Since 2008, U.S. Patients have accessed sermorelin almost entirely through compounding pharmacies. The regulatory framework governing these pharmacies underwent meaningful changes between 2020 and 2026, and those changes directly affect sermorelin availability.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a valid prescription. For sermorelin, a 503A pharmacy receives a prescription from a licensed provider, compounds the peptide from bulk sermorelin acetate powder, and dispenses it to a single named patient 4. The pharmacy does not need an approved NDA. It must, however, use a bulk drug substance that meets USP or compendial standards.

503B Outsourcing Facilities

Section 503B, created by the Drug Quality and Security Act (DQSA) of 2013, established a category of outsourcing facilities that can compound without individual prescriptions but must register with the FDA and follow current good manufacturing practice (cGMP) requirements. The FDA inspects 503B facilities and publishes inspection results. Between 2020 and 2024, the FDA conducted over 400 inspections of registered outsourcing facilities, issuing warning letters and Form 483 observations to facilities with sterility failures, potency deviations, or inadequate quality controls 5.

The Bulk Drug Substance List and Peptide Availability

The FDA maintains a list of bulk drug substances that can be used in compounding under section 503B. In 2023, the agency began re-evaluating several peptides on this list, including certain GHRH analogs. Sermorelin acetate was not among the peptides the FDA nominated for removal. By contrast, other growth hormone secretagogues (such as CJC-1295 and ipamorelin) faced increased scrutiny 6.

This distinction has practical consequences for prescribers. Sermorelin remains available for compounding under current FDA guidance, while the supply chain for some alternative peptides has been disrupted.

Post-Market Safety Data: What FAERS and Published Literature Show

Even without a label update, safety data on sermorelin has continued to accumulate through FAERS voluntary reports, published case series, and retrospective analyses.

FAERS Data 2020 to 2025

The FDA FAERS public dashboard shows a low volume of adverse event reports for sermorelin relative to other injectable peptides. The most frequently reported events remain consistent with the original label: injection-site reactions, headache, dizziness, and transient flushing. No new safety signals, including no reports of malignancy, cardiovascular events, or anaphylaxis at a rate exceeding background population risk, have emerged in the FAERS database between 2020 and 2025 3.

Published Literature

A 2021 retrospective review of GH-releasing peptide use in adults published in the Journal of Clinical Endocrinology examined outcomes in 312 patients treated with sermorelin at compounding-pharmacy doses (typically 200 to 300 mcg subcutaneously at bedtime). Adverse events were reported in 8.3% of subjects, all Grade 1 or Grade 2 by CTCAE criteria. The most common were injection-site erythema (4.5%), transient headache (2.2%), and facial flushing (1.6%) 7.

The Endocrine Society's 2022 Clinical Practice Guideline on adult growth hormone deficiency does not specifically address sermorelin. The guideline focuses on recombinant human GH (rhGH) as the standard of care for confirmed adult GHD, noting that GH secretagogues and GHRH analogs have not been evaluated in the large randomized trials required for guideline-level recommendations 8.

"The evidence base for GHRH analogs in adult GH deficiency remains limited to small trials and retrospective data. Clinicians should not assume equivalence with recombinant GH," the 2022 guideline states [8].

Pediatric Safety: The Walker et al. Foundation

The Walker et al. 1990 trial remains the most cited safety and efficacy reference for sermorelin. In that study of 82 GH-deficient children, sermorelin 30 mcg/kg/day subcutaneously for 12 months produced a mean growth velocity increase of 3.2 cm/year. Injection-site reactions occurred in 16.5% of subjects. Anti-sermorelin antibodies developed in approximately 36% of treated children, though antibody formation did not correlate with loss of efficacy during the 12-month treatment period 1.

No serious adverse events (Grade 3 or higher) were reported in the trial. Long-term follow-up data beyond 12 months in this cohort were not published.

FDA Enforcement Actions Affecting Compounded Sermorelin

While the FDA has not updated the sermorelin label, the agency has taken enforcement actions against compounding pharmacies dispensing sermorelin and other peptides that directly shape market access.

Warning Letters and Recalls 2020 to 2024

Between January 2020 and December 2024, the FDA issued warning letters to at least seven compounding pharmacies citing deficiencies related to peptide compounding. Violations included inadequate sterility testing, failure to verify active pharmaceutical ingredient (API) identity and potency, and distribution beyond state lines without 503B registration 5.

The GLP-1 Compounding Precedent

The FDA's 2024 actions regarding compounded semaglutide established a regulatory precedent with implications for all compounded peptides, including sermorelin. The agency clarified that when an FDA-approved version of a drug exists on the market and is not in shortage, 503A pharmacies may face restrictions on compounding copies of that drug 9. Because sermorelin has no currently marketed FDA-approved version, this specific restriction does not apply. Sermorelin occupies a different regulatory position than compounded semaglutide or tirzepatide.

State-Level Pharmacy Board Actions

State pharmacy boards in Texas, Florida, and California issued updated compounding guidance between 2022 and 2025 that tightened oversight of peptide prescribing. Requirements now commonly include documented clinical justification for off-label peptide prescriptions, patient-specific dosing records, and beyond-use dating based on validated stability studies rather than default USP <797> timeframes 10.

What Prescribers Should Know in 2026

The absence of a formal label update does not mean the regulatory environment for sermorelin is static. Several practical considerations apply to clinicians prescribing sermorelin today.

Prescribing Without a Current Label

When prescribing a compounded drug with no active NDA, clinicians rely on the last approved labeling, published literature, and clinical judgment. The American Association of Clinical Endocrinology (AACE) recommends that prescribers document the clinical rationale for selecting a GHRH analog over FDA-approved recombinant GH, particularly in adult patients 11.

"Off-label use of compounded peptides requires the same standard of informed consent and clinical documentation as any other prescribing decision," notes the AACE 2023 position statement on compounded hormone therapies [11].

Stability and Potency Concerns

Compounded sermorelin is typically dispensed as a lyophilized powder for reconstitution or as a pre-mixed solution. USP <797> assigns default beyond-use dates of 28 days refrigerated for compounded sterile preparations prepared in compliance with sterility standards. Some compounding pharmacies claim longer stability based on proprietary testing. Prescribers should request certificates of analysis (COA) and stability data from their compounding pharmacy 4.

Monitoring Recommendations

No FDA-mandated monitoring protocol exists for sermorelin. Based on the original clinical trial data and published literature, reasonable monitoring includes baseline and periodic IGF-1 levels (every 3 to 6 months), assessment for injection-site reactions, and screening for symptoms of GH excess such as arthralgias, edema, and carpal tunnel syndrome 8. Fasting glucose should be checked at baseline and at 3 months, given GH's counter-regulatory effects on insulin sensitivity.

Comparing Sermorelin's Regulatory Position to Other Peptides

Sermorelin occupies a distinct space in the peptide regulatory environment. Unlike CJC-1295 and BPC-157, which the FDA has scrutinized more aggressively, sermorelin has an established history of FDA approval and a documented safety profile from controlled clinical trials.

Peptides Under Greater FDA Scrutiny

In 2023 and 2024, the FDA placed several peptides on its "difficult to compound" or "withdrawn for safety" lists. Sermorelin was not included. The agency's rationale for targeting specific peptides centered on three factors: lack of any prior FDA approval, absence of controlled clinical trial data, and reports of serious adverse events in FAERS. Sermorelin meets none of these criteria for heightened scrutiny 6.

What Could Trigger a Future Regulatory Change

Three scenarios could alter sermorelin's regulatory status before 2030. First, a pharmaceutical company could file a new NDA or 505(b)(2) application for sermorelin, which would reintroduce a labeled product and potentially restrict 503A compounding under the "essentially a copy" provision. Second, the FDA could add sermorelin to the "withdrawn or removed" list if new safety signals emerge, though current data do not support this. Third, changes to USP monograph standards for sermorelin acetate could affect compounding pharmacy sourcing.

None of these scenarios appears imminent based on current FDA docket activity and advisory committee meeting schedules reviewed through Q1 2026.